Medical Device Fraud Cases: The Contracts, Claims and Concealed Failures

Medical device fraud cases expose payments that influence product choice, sales advice that changes a bill, and device failures a company keeps from doctors and patients. The surgeon may choose the implant while the hospital buys it and bills Medicare for the health care provided. A sales representative, quality specialist or reimbursement employee can know the part of that transaction the claim never shows: why the surgeon received a contract, what the company knew about the device, or where the billing instructions came from.

How Does Reimbursement Work for Medical Devices?

Medicare usually includes an implanted device in its payment for the procedure or hospital stay. The hospital pays for the implant, while the physician may control the choice of brand and model. In a consignment arrangement, the manufacturer’s inventory can sit at the hospital until use triggers the sale.

That puts the commercial decision inside the clinical one. The representative who manages implant trays may also support the operation. Sales records, operating-room records and the hospital bill describe different parts of the same transaction.

FDA authorization, Medicare coverage, coding and payment each answer a different question: whether a device may be marketed, whether Medicare covers the care, how the service is described and how much it pays. A manufacturer’s reimbursement advice can reach the claim through the provider’s billing staff.

The 2020 Journal of Forensic and Investigative Accounting paper A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud explains why the payment request matters: the False Claims Act inquiry follows the claim and the effect of the false statement on payment. For a device insider, that means connecting the commercial or product evidence to the care the government paid for.

Medical Device Fraud Cases by Company and Outcome

These healthcare fraud settlements show how a commercial decision can change the government’s bill. The alleged influence can enter at the surgeon’s product choice, the supplier’s sales pitch or the billing screen.

Spinal Implant Fraud Cases

Spinal implant fraud cases show how consulting, intellectual-property purchases and distributor ownership can tie a surgeon’s income to implant selection. Other spine cases concern promotion and reimbursement instructions that change which procedure gets billed.

Life Spine and Innovasis Put Consulting Beside Product Use

Life Spine agreed to pay $5.5 million in November 2019 and made factual admissions. It acknowledged that about 21 of its 30 largest users received consulting fees, royalties or intellectual-property payments. Surgeons receiving those payments generated about half its domestic spinal-product sales. Management compared payments with product use, including a return-on-investment calculation, and urged surgeons to use more when sales fell.

We find the management report more revealing than the contract heading. The company was measuring what it paid a surgeon against what that surgeon’s implant choices brought back. Consulting, scored by sales.

The Justice Department’s $12 million Innovasis settlement in May 2024 covered the company and two executives together. The government alleged that payments induced use of spinal products in procedures for Medicare beneficiaries. The government also alleged that some purported intellectual property had no valuation before purchase and never contributed to meaningful product development. The alleged conduct ran from January 2014 through December 2022.

SpineFrontier and Reliance Moved the Payment Through Another Company

The government’s SpineFrontier complaint alleged that a supposed consulting intermediary paid surgeons for implanting its devices in procedures billed to federal health programs. Its account of why that intermediary existed is blunt:

The government’s allegation was payment for product use dressed as product evaluation. In a separate civil settlement, a surgeon admitted estimating consulting hours from how many times he used a SpineFrontier product in a month instead of tracking actual consulting time.

Reliance Medical Systems took the distributor route. Its July 2022 settlement of $1 million covered Reliance, two physician-owned distributors and two owners. The government alleged referral-based distributions and removal of physicians who generated insufficient referrals. The surgeon choosing the implant could also profit from its sale to the hospital.

NuVasive, TranS1 and Norian Changed the Promotion or the Claim

NuVasive’s $13.5 million settlement in July 2015 resolved off-label promotion and kickback allegations. The government alleged that a seemingly independent surgical society was created, funded and operated solely by NuVasive, with speaker fees and expenses flowing through its events.

TranS1, identified at settlement as Baxano Surgical, agreed to pay $6 million in July 2013. Its case concerned allegedly false reimbursement claims for minimally invasive spine procedures, including the company’s promotion and coding advice. Here the sales message reached the government’s bill through the description of the procedure.

Synthes and Norian’s October 2010 civil agreement required Synthes to pay $138,000. The government alleged false safety and efficacy representations concerning bone cement used for vertebral compression fractures, leading to claims or purchases for Medicare, TRICARE and Veterans Affairs beneficiaries. Norian XR’s labeling warned against that use.

Cardiac Device Fraud Cases

Cardiac device fraud cases reach research payments, meals, defective implants, replacement credits and hospital coverage decisions. The same kind of device can enter a case through very different parts of the business.

Payments for Implant Choice

St. Jude Medical agreed to a $16 million settlement in January 2011 over allegations that post-market studies and a registry paid physicians to choose its pacemakers and defibrillators. The government alleged that the company collected data while using the payments to increase sales. On the government’s account, the research payments served the sales effort.

Abiomed’s $3.1 million settlement in March 2018 concerned meals allegedly intended to induce heart-pump purchases. The allegations included false attendee information on expense reports. The guest list was part of the sales evidence.

Defective Devices and Replacement Credits

Boston Scientific, Guidant LLC, Guidant Sales and Cardiac Pacemakers agreed to a $30 million civil settlement in October 2013 over allegedly selling defective implantable heart devices for Medicare patients during 2002 through 2005.

Guidant LLC’s September 2011 settlement of $9.25 million concerned a different payment: allegedly withheld warranty credits or rebates inflated replacement costs to federal programs.

St. Jude’s May 2012 settlement of $3.65 million likewise concerned withheld credits, specifically when billing Defense and Veterans Affairs for replacement pacemakers and defibrillators. Those cases put the replacement invoice beside the manufacturer’s warranty promise.

Hospital Coverage Decisions

The Justice Department announced more than $250 million in hospital settlements in October 2015 over implantable-defibrillator claims allegedly submitted during Medicare’s required waiting periods. The claims concerned 2003 through 2010. The alleged decision was when the hospital implanted and billed for the device.

Cape Cod Hospital’s $24.3 million settlement in May 2024 included admissions that it failed to follow Medicare requirements for transcatheter aortic valve replacement. The case concerned independent examinations and documentation and sharing of clinical judgments for claims from November 2015 through December 2022. The hospital’s patient-review process was the issue.

False Billing for Durable Medical Equipment

Durable medical equipment cases can follow a supplier’s recurring bill, the quantity shipped or the order that supposedly authorized delivery. Lincare agreed to a $25.5 million settlement in February 2024 and admitted that it sometimes continued seeking monthly ventilator payments while aware that patients were not using the devices.

In the criminal cases described in the Centers for Medicare & Medicaid Services’ June 2025 enforcement announcement, prosecutors alleged another route: stolen beneficiary information, artificial-intelligence recordings of supposed consent, and equipment companies held in nominal owners’ names. The charging allegations included claims for products beneficiaries did not request, need or receive. The order, consent recording and delivery record can each tell a different story from the bill.

Concealed Failures and the People Who Knew

The Ancure case connected operating-room knowledge to reports withheld from the FDA. In its guilty plea, EndoVascular Technologies, a Guidant subsidiary, admitted failing to file an additional 2,628 device reports. The company had filed 172. The Justice Department’s June 2003 announcement described company representatives present during every operation and malfunction reports repeatedly tabulated for management.

The plea account also described representatives teaching doctors to break the delivery system’s handle when it became stuck. The technique had not been tested, appeared in no product instructions and continued to be described during surgeries after a patient died and employees said the FDA needed to know.

We see something much more specific here than a reporting backlog. The people selling the device were in the room when it failed. Management received the reports. Doctors were taught a workaround the instructions never mentioned.

EndoVascular Technologies agreed to a separate $49 million civil settlement concerning payments by Medicare, Medicaid and Veterans Affairs for the devices.

Olympus Medical Systems Corporation’s December 2018 guilty plea concerned misbranded duodenoscopes and missing adverse-event reports. The criminal account described an outside expert’s findings about crevices that could harbor bacteria and resist cleaning.

Repeat Medical Device Settlements

We see repeat medical device settlements reach different parts of the same business: physician training, replacement credits and services offered to equipment suppliers.

Biotronik’s November 2014 settlement of $4.9 million concerned allegedly improper physician payments, including meals and inflated advisory-board payments. Its July 2022 settlement of $12.95 million concerned inducements for pacemakers and defibrillators, including excessive or nonexistent physician training. The government alleged that the company’s compliance department had warned about salespeople’s influence over the training program.

St. Jude’s cases moved from allegedly improper rebates in 2010 to research payments, replacement credits and, in July 2021, a $27 million defective-device settlement. That last settlement covered alleged sales from November 2014 through October 2016. Abbott acquired St. Jude in 2017.

Respironics’ March 2016 settlement of $34.8 million resolved allegations of free resupply call-center services for suppliers whose patients used its masks. The government alleged that the charge depended on how many patients used competitors’ masks.

In September 2022, Philips RS North America, formerly Respironics, agreed to pay over $24 million over alleged inducements involving physician prescribing data supplied to equipment companies.

Philips RS North America’s corporate integrity agreement took effect in August 2022. Its 2024 FDA consent decree concerned CPAP devices.

The Department of Health and Human Services Office of Inspector General recorded a $15,000 payment by Exactech on June 9, 2014 for failures under its integrity agreement that included employee and contractor screening and distribution of required policies.

Civil Settlements and Criminal Outcomes

The jury acquitted Vascular Solutions and its chief executive in February 2016. The company had separately agreed to a $520,000 civil settlement in July 2014 over allegations involving promotion for perforator-vein ablation.

Stryker Corporation’s February 2012 securities filing reported that the Justice Department dismissed the felony charges against Stryker Biotech and all charges against the employees in the OP-1/Calstrux prosecution. The company resolved its criminal case on a misdemeanor.

What Evidence Is Needed to Prove Fraud?

We work with device insiders to connect a payment, product or instruction to a treatment decision and the resulting claim. Life Spine’s surgeon-use reports explained what management measured. SpineFrontier’s consulting submissions explained what the government said it was paying for. Ancure’s complaint tabulations showed what reached management. A billing employee or sales representative may know how those records connect even when they sit in different departments.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Arthrex settlement announced a $2.5 million whistleblower award.

Your Part of the Device Business Matters

If you recognize the consulting arrangement, the missing failure report or the billing instruction, talk with our medical device fraud whistleblower experts. We develop the case strategy with you and bring in medical device whistleblower lawyers who understand how product decisions reach government claims. We stay with you through the process, using your knowledge of the business to build your strongest medical device whistleblower case.